Total Payments
$11,389
2024 Payments
$1,796
Companies
69
Transactions
698
Medicare Patients
2,222
Medicare Billing
$301,266
Payment Breakdown by Category
Food & Beverage$10,606 (93.1%)
Education$782.69 (6.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,606 | 686 | 93.1% |
| Education | $782.69 | 12 | 6.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,142 | 85 | $0 (2024) |
| Janssen Biotech, Inc. | $1,001 | 61 | $0 (2024) |
| Merck Sharp & Dohme LLC | $839.96 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $684.25 | 41 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $551.08 | 25 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $533.16 | 35 | $0 (2024) |
| PFIZER INC. | $476.97 | 28 | $0 (2024) |
| Incyte Corporation | $475.06 | 25 | $0 (2024) |
| Celgene Corporation | $434.50 | 29 | $0 (2024) |
| Genentech USA, Inc. | $420.64 | 30 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,796 | 95 | ABBVIE INC. ($186.85) |
| 2023 | $1,769 | 93 | PFIZER INC. ($195.53) |
| 2022 | $1,512 | 88 | Incyte Corporation ($175.18) |
| 2021 | $1,245 | 77 | Eisai Inc. ($149.11) |
| 2020 | $711.50 | 50 | Amgen Inc. ($68.49) |
| 2019 | $1,138 | 83 | Janssen Biotech, Inc. ($233.38) |
| 2018 | $1,583 | 112 | Janssen Biotech, Inc. ($427.63) |
| 2017 | $1,635 | 100 | E.R. Squibb & Sons, L.L.C. ($234.45) |
All Payment Transactions
698 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: Oncology | ||||||
| 12/10/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Education | In-kind items and services | $83.99 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $28.14 | General |
| Category: NONE | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug), Nubeqa, Stivarga | Food and Beverage | In-kind items and services | $25.63 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Oncology | ||||||
| 11/20/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: IMMUNOLOGY | ||||||
| 10/27/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $11.35 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: HORMONE THERAPY | ||||||
| 10/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.02 | General |
| 10/21/2024 | Genentech USA, Inc. | Columvi (Biological), Gazyva, Itovebi | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: BioOncology | ||||||
| 10/16/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.75 | General |
| Category: Hematology/Oncology | ||||||
| 10/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Rare Disease | ||||||
| 09/24/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: Oncology | ||||||
| 09/16/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Oncology | ||||||
| 09/12/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $6.25 | General |
| Category: HEMATOLOGY | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Immunology | ||||||
| 09/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 507 | 15,967 | $216,311 | $54,679 |
| 2022 | 14 | 621 | 26,453 | $353,759 | $85,436 |
| 2021 | 11 | 563 | 1,664 | $229,976 | $60,063 |
| 2020 | 12 | 531 | 27,991 | $343,868 | $101,089 |
Total Patients
2,222
Total Services
72,075
Medicare Billing
$301,266
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 126 | 276 | $127,382 | $26,488 | 20.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 15 | 15,000 | $30,000 | $13,191 | 44.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $15,118 | $5,329 | 35.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 48 | $14,094 | $3,520 | 25.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 129 | 285 | $12,385 | $2,123 | 17.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 120 | 236 | $8,615 | $1,982 | 23.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 26 | $5,302 | $1,398 | 26.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 23 | 57 | $3,415 | $647.36 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 136 | 363 | $165,528 | $35,043 | 21.2% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 23 | 24,000 | $48,000 | $21,505 | 44.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 80 | $32,000 | $9,894 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $15,662 | $5,730 | 36.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 144 | 393 | $16,899 | $3,019 | 17.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 12 | 81 | $16,200 | $2,203 | 13.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 13 | 126 | $25,200 | $1,809 | 7.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 22 | 28 | $5,600 | $1,728 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 23 | $6,624 | $1,685 | 25.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 24 | 85 | $5,015 | $1,044 | 20.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 134 | 293 | $10,548 | $869.25 | 8.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 15 | $3,000 | $543.70 | 18.1% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2022 | 13 | 33 | $2,145 | $275.89 | 12.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 14 | 892 | $1,338 | $85.07 | 6.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 134 | 300 | $133,492 | $32,412 | 24.3% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 14 | 53 | $21,200 | $7,121 | 33.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 66 | $19,008 | $5,079 | 26.7% |
About Dr. Ruby Hanna, M.D
Dr. Ruby Hanna, M.D is a Hematology & Oncology healthcare provider based in Mountain Lakes, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1750502811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruby Hanna, M.D has received a total of $11,389 in payments from pharmaceutical and medical device companies, with $1,796 received in 2024. These payments were reported across 698 transactions from 69 companies. The most common payment nature is "Food and Beverage" ($10,606).
As a Medicare-enrolled provider, Hanna has provided services to 2,222 Medicare beneficiaries, totaling 72,075 services with total Medicare billing of $301,266. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Mountain Lakes, NJ
- Active Since 05/02/2007
- Last Updated 06/28/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1750502811
Products in Payments
- OPDIVO (Biological) $807.76
- KEYTRUDA (Biological) $795.30
- IMBRUVICA (Drug) $579.78
- Imbruvica (Drug) $383.99
- Lenvima (Drug) $325.37
- DARZALEX (Biological) $289.02
- JAKAFI (Drug) $285.29
- Erleada (Drug) $245.41
- Enhertu (Drug) $229.17
- KISQALI (Drug) $214.74
- Stivarga (Drug) $213.46
- XPOVIO (Drug) $195.24
- FASLODEX (Drug) $166.17
- XTANDI (Drug) $162.40
- JEVTANA (Drug) $141.86
- EMPLICITI (Biological) $141.16
- REBLOZYL (Biological) $137.52
- IBRANCE (Drug) $135.47
- JADENU (Drug) $131.88
- Pomalyst (Drug) $130.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Mountain Lakes
Christopher Tully
Hematology & Oncology — Payments: $38,654
Hematology & Oncology $38,654
Dr. Muhammad Abbasi, M.d, M.D
Hematology & Oncology — Payments: $33,999
Hematology & Oncology $33,999
Jason Levitz, M.d, M.D
Hematology & Oncology — Payments: $24,538
Hematology & Oncology $24,538
Naveed Jan, M.d, M.D
Hematology & Oncology — Payments: $23,098
Hematology & Oncology $23,098